Recardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the positive study results of Recardio’s Phase 2 clinical study in Acute Myocardial Infarction were presented on Saturday, May 21, 2022, during the Latebreaker Session […]
Tag: STEMI
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction
Iocyte AMI-3 Trial to Assess Effectiveness and Safety of FDY-5301 in Improving Outcomes for Anterior STEMI Patients Undergoing Primary PCI SEATTLE, May 10, 2022 (GLOBE NEWSWIRE) — Faraday Pharmaceuticals, Inc., today announced the enrollment of the first patient in its Iocyte […]
Miracor Medical’s PiCSO® System Receives CE Mark
AWANS, Belgium–(BUSINESS WIRE)–Miracor Medical SA (Miracor Medical) has announced the award of the CE Mark for its latest generation of PiCSO Impulse Catheter and PiCSO Impulse Console, which is indicated for the treatment of anterior STEMI patients. The new system […]
Recardio’s Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin Now Enrolling and Recruiting in All Global Centers
Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction is now enrolling and recruiting in all multiple European and U.S. […]
PiCSO therapy reduces infarct size in STEMI patients.
AWANS, Belgium, May 24, 2018 /PRNewswire/ — Miracor Medical SA announced today the clinical results from the physician-sponsored OxAMI-PiCSO study were published in the EuroIntervention journal and presented at the Hotline session of the EuroPCR conference by Dr. Giovanni Luigi De Maria, MD, the Heart Centre, Oxford University Hospitals, Oxford, […]